Imaging cancer-associated fibroblasts in lung cancer patients receiving immunotherapy
Official title: Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors
Run by Jules Bordet Institute · NCT06107608 · Data updated 2026-11-12
This study is testing whether a special imaging technique can help doctors see how certain cells in lung cancer patients respond to immunotherapy and predict their treatment outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 58 (estimated) |
| Sponsor | Jules Bordet Institute Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Brussels) |
| Status | Recruiting |
| Started | June 13, 2023 |
| Main results expected | July 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | March 31, 2025 |
| Trial ID | NCT06107608 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with pathologically-proven NSCLC who are set to receive anti-PD-(L)1 therapy, either alone or in combination with other treatments.
✕Probably not a fit
Patients with specific genetic mutations (EGFR, ALK, ROS1) or those who have had recent cancer treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the relationship between fibroblast activation protein (FAP) expression and patient outcomes in individuals with non-small cell lung cancer (NSCLC) undergoing immunotherapy. Using the PET radiotracer 68Ga-FAPI, the study aims to visualize and quantify cancer-associated fibroblasts (CAFs) before and during treatment. The approach is non-invasive and seeks to identify predictive biomarkers that may enhance the understanding of tumor dynamics and patient response to therapy.
Why it matters
Potential benefit: If successful, this study could improve the personalization of immunotherapy for lung cancer patients by identifying which individuals are more likely to benefit from treatment.
How similar studies have gone: While the use of FAP imaging in cancer is a growing area, this specific approach in NSCLC with immunotherapy is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age above 18 years. * Pathologically- proven non-small-cell lung cancer (NSCLC). * Proposed for treatment with anti-PD-(L)1 alone or in combination with chemotherapy and/or anti-CTLA4 in the advanced setting. * ECOG Performance status ≤2. * Patient's written informed consent obtained prior to any study procedure. Exclusion Criteria: * Surgery and/or radiotherapy to thoracic region within the last 8 weeks or anti-cancer systemic therapy within the last 2 weeks. * Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and c-ros oncogene (ROS1) mutations. * Pregnant and lactating women * Previous or concurrent malignancy diagnosed within the last 2 years except adequately treated in situ carcinoma of the cervix uteri, localised (T1N0) low grade (Gleason score 6) prostate cancer undergoing active surveillance and basal or squamous cell skin cancer. * Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
Where it's running
-
Institut Jules Bordet
Brussels, Belgium Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Patient-specific MRD liquid biopsy for resected NSCLC
This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.
-
Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases
This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.
-
Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies
This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery
This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.
-
HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC
This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.